Fulgent Genetics

biotechnology company

FLGT Nasdaq ISIN US3596641098 SEC CIK 1674930 LEI 549300CL6P01M68QJ404
Follow Fulgent Genetics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $90.4M +7.5% vs same quarter last year
Net income −$13.2M −99% vs same quarter last year
EPS, diluted -
Operating cash flow $109.2M +883.5% vs same quarter last year
Revenue by quarter
$76.2M
$73.5M
$81.8M
$84.1M
$83.3M
$71.1M
$85.4M
$90.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1BFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$322.7M−$60.5M
FY24$283.5M−$42.7M
FY23$289.2M−$167.8M
FY22$619M$143.4M
FY21$992.6M$507.4M
FY20$421.7M$214.3M
FY19$32.5M−$411K
FY18$21.4M−$5.6M
FY17$18.7M−$2.5M
FY16$18.3M−$5.3M
FY15$9.6M−$8.3M
FY14$1.3M−$4.3M
FY13--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400%−200%0%200%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2540.6%−28.2%−18.8%
FY2437.8%−26.1%−15.1%
FY2336.1%−67.6%−58%
FY2259.3%28.8%23.2%
FY2178.3%68.1%51.1%
FY2078.7%68.8%50.8%
FY1956.6%−1.3%−1.3%
FY1849.9%−23.7%−26.3%
FY1754.3%−18.6%−13.4%
FY1663.2%5%−29.3%
FY1547.1%−52.3%−86.8%
FY1426.8%−77.5%−335.1%
FY13---
Free cash flowOperating cash flow minus capital expenditure
−$200M$0$200M$400M$600MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$124.2M
FY24−$19.3M
FY23$4.8M
FY22$234.7M
FY21$514.8M
FY20$105.5M
FY19$4.3M
FY18−$3M
FY17−$1.6M
FY16$617K
FY15−$3.1M
FY14−$5.1M
FY13-
Returned to shareholdersDividends paid and shares bought back
$0$20M$40M$60M$80MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$10.9M
FY24$225K
FY23$25.1M
FY22$74.3M
FY21-
FY20$62K
FY19$21K
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Fulgent Genetics
  • Healthcare median
−400%−300%−200%−100%0%100%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFulgent GeneticsHealthcare median
FY25−18.8%−30.6%
FY24−15.1%−47%
FY23−58%−58%
FY2223.2%−80.4%
FY2151.1%−71.8%
FY2050.8%−62.2%
FY19−1.3%−46.2%
FY18−26.3%−49.6%
FY17−13.4%−45.9%
FY16−29.3%−36%
FY15−86.8%−37.8%
FY14−335.1%−35.5%
FY13-−37.1%